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Background: In patients with cardiac resynchronization therapy defibrillators (CRT-Ds), intracardiac
impedance measured by dedicated CRT-D software may be used to monitor hemodynamic changes. We
investigated the relationship of hemodynamic parameters assessed by intracardiac impedance and by
echocardiography in a controlled clinical setting.
Methods: The study enrolled 68 patients (mean age, 66 ± 9 years; 74% males) at 12 investigational sites.
The patients had an indication for CRT-D implantation, New York Heart Association class II/III symptoms,
left ventricular ejection fraction 15%e35%, and a QRS duration 150 ms. Two months after a CRT-D
implantation, hemodynamic changes were provoked by overdrive pacing. Intracardiac impedance was
recorded at rest and at four pacing rates ranging from 10 to 40 beats/min above the resting rate. In
parallel, echocardiography measurements were performed. We hypothesized that a mean intra-
individual correlation coefficient (rmean) between stroke impedance (difference between end-systolic
and end-diastolic intracardiac impedance) measured by CRT-D and the aortic velocity time integral
(i.e., stroke volume) determined by echocardiography would be significantly larger than 0.65.
Results: The hypothesis was evaluated in 40 patients with complete data sets. The rmean was 0.797, with a
lower confidence interval bound of 0.709. The study hypothesis was met (p ¼ 0.007). A stepwise
reduction of stroke impedance and stroke volume was observed with increasing heart rate.
Conclusions: Intracardiac impedance measured by implanted CRT-Ds correlated well with the aortic
velocity time integral (stroke volume) determined by echocardiography. The impedance measurementsal; CRT, cardiac resynchroni-
astolic impedance; ESZ, end-
diac impedance; ICI-MF, ICI
end-diastolic diameter; LVEF,
ion; RV, right ventricular; SZ,
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Heart failure (HF) is a global pandemic affecting an estimated 26
million people worldwide and resulting in >2 million hospitaliza-
tions each year [1]. Despite advances in pharmacological and device
therapies, the 12-month mortality and hospitalization rates remain
about 17% and 44% for hospitalized HF patients, and 7% and 32% for
stable, ambulatory HF patients, respectively [2]. Cardiac resynch-
ronization therapy (CRT) can improve cardiac function and reduce
morbidity and mortality of symptomatic patients with a reduced
left ventricular ejection fraction (LVEF; 35%) and a prolonged QRS
duration (130 msec) [2]. To terminate potentially lethal ventric-
ular arrhythmias, most CRT devices integrate a defibrillator (CRT-D
device). But the risks of progressive deterioration of HF, hospitali-
zation (incurring high treatment costs) [3], and death remain high
because of the natural history of HF and the fact that approximately
30% of patients do not respond to CRT [2,4].
Remote monitoring of CRT(-D)s has been adopted as a new
standard of device and patient follow-up care where alert-driven
in-person evaluations replace most of the routine device follow-
ups [4e8]. Addition of a reliable hemodynamic sensor to a CRT(-
D) would allow a continuous monitoring of cardiac function to
reduce acute HF decompensations and achieve hemodynamic
optimization by CRT(-D) self-adaptation or manual reprogramming
prompted by telemonitored data. An effective implantable hemo-
dynamic sensor is currently available as a stand-alone monitor of
pulmonary artery pressurewhose remote transmissions are used to
optimize medication and patient management [7,9].
Hemodynamic changes may alternatively be assessed by intra-
cardiac impedance (ICI) changes measured using ‘standard’ CRT-D
devices with dedicated software. The principle has been explored
in animals and in 14 patients by invasive methods [10e14], and in
another study of 15 ischemic patients by minimally invasive
methods [15]. Recently, the ICI measurement feature (ICI-MF) has
been integrated for investigational purposes in themarket-released
Lumax 740 HF-T and the successor CRT-D device models (Biotronik
SE & Co. KG; Berlin, Germany). The present study investigates the
relationship of hemodynamic parameters assessed by the ICI-MF
and by echocardiography in a controlled clinical setting.2. Methods
The non-randomized Monitoring of Hemodynamics in Heart
Failure Patients by Intracardiac Impedance Measurement (BIO.-
Detect HF II) study was performed at 12 investigational sites in
Germany, Denmark, and The Netherlands (see Appendix). The
study was conducted in compliance with good clinical practice
guidelines and the Declaration of Helsinki, including approval of
the study protocol by appropriate national and local ethics com-
mittees, and study registration with ClinicalTrials.gov, number
NCT01711281. Patients provided written informed consent.2.1. Patients
Consenting adults were enrolled if they had an accepted indi-
cation for CRT-D implantation, the New York Heart Association
(NYHA) class II or III HF with ischemic or non-ischemic etiology or210
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ventricular end-diastolic diameter (LVEDD) 55 mm, LVEF 15%e
35%, and a QRS duration 150 msec.
Patients were excluded if they had an already implanted CRT
device, persistent atrial fibrillation, aortic valve stenosis, significant
aortic regurgitation (more than a trace of aortic valve insufficiency
or/and vena contracta >3 mm), aortic valve prosthesis, heart
transplant (or a candidate status), a planned or previous (within 3
months) heart surgery, need for chronic renal dialysis, or life ex-
pectancy 1 year due to a non-cardiac disease. Also those partici-
pating in another clinical trial, or who were not implanted with all
components of the CRT-D system as specified below, were
excluded.2.2. CRT-D system
The Lumax 740 HF-T and its successor devices integrate the ICI-
MF and Biotronik Home Monitoring® technology capable of auto-
matic, daily transmissions of various parameters [16,17], including
ICI data for investigational purposes. The ICI-MF has been market
approved in Europe based on an extensive risk-benefit analysis. The
benefit is currently merely hypothetical, and activation of the ICI-
MF is therefore restricted to clinical trials.
While no additional material beyond standard CRT-D system
needed to be implanted, the use of a true bipolar right ventricular
(RV) defibrillation lead [18] and of a bipolar left ventricular (LV)
lead with at least 15-mm distance between the tip and the ring
electrodes is necessary for ICI-MF and was mandated by study
protocol. This minimum distance was estimated based on the
technical requirements needed to guarantee an adequate intra-
cardiac impedance, given the exact measurement hardware and
conditions. Originally, it was verified by numerical models but also
proved to be appropriate in a previous study [15]. Right atrial and
RV leads were implanted endocardially, and LV leads were
implanted in a sidebranch of the coronary sinus.2.3. Working principle of ICI measurements
Pseudo-continuous ICI curves are generated by injecting a sub-
threshold current between the RV lead tip and coil, and sampling
voltage via the LV electrodes (Fig. 1A) [10]. After averaging ICI
curves for a certain number of heart cycles, four parameters are
derived:
 EDZ: End-diastolic impedance is the minimum ICI value during
the heart cycle (Fig. 1B).
 ESZ: End-systolic impedance is the maximum ICI value during
the heart cycle (Fig. 1C).
 SZ ¼ ESZ - EDZ: Stroke impedance is the difference between ESZ
and EDZ (Fig. 1D) [11,13]. As a rule, the larger the stroke volume,
the greater the stroke impedance.
 Zmean: Mean impedance is the mean value of the averaged ICI
values for each heart cycle in an ICI measurement window.
ICI provides relative rather than absolute measures of hemo-
dynamic parameters. To estimate changes in stroke volume, ICI has
to be collected as serial measurements over a period of time. from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
Fig. 1. Panel A: Working principle of intracardiac impedance measurements. Sub-threshold current (I1) is injected between two electrodes on the right ventricular lead (tip and coil)
and is conducted by blood and tissue. The resultant voltage (V2) is sampled via two electrodes on the left ventricular lead (tip and ring). Current pulses of 30-msec width per phase
are delivered every 8 msec to generate impedance curve for the entire heart cycle. Panels B and C: Blood has lower electrical resistance than myocardial tissue. A maximally filled
left ventricle with blood at the end of diastole is therefore associated with impedance minimum, and a maximally emptied left ventricle at the end of systole is associated with
impedance maximum. Panel D: Idealized depiction of relationship between ECG, left ventricular volume, and intracardiac impedance curve during a heart cycle.
P.-P.H.M. Delnoy, K.-J. Gutleben, N.E. Bruun et al. Indian Pacing and Electrophysiology Journal 21 (2021) 209e218Changes in stroke volume can be provoked acutely by overdrive
pacing or medications (e.g., dobutamine) and may be observed
chronically as a consequence of progressive HF or cardiac
remodelling.2.4. Acute and chronic ICI measurement options
Depending on themeasurement purpose, two different working
options can be used: acute ICI measurement and chronic ICI
measurement.
Acute ICI measurement is suited to monitor hemodynamic
changes in a controlled clinical setting. ICI curves are continuously
stored in the programmer memory, to be retrieved and processed
later. To ensure patient safety, acute ICI measurements can be
activated only if an immediate RV impedance and pacing threshold
test ensures a non-capture safety margin of at least 3.5 related to
600-mA current pulses injected for the measurements. To illustrate
the processing of the acute ICI data, an exemplary recording of raw211
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and as transmitted to the programmer via real-time telemetry is
depicted along with a synchronous ECG measurement (Fig. 2).
Chronic ICI measurement is aimed at monitoring slow hemo-
dynamic changes over time. To ensure safety of ambulatory pa-
tients under all possible conditions, the current amplitude is
reduced from 600 mA to 200 mA. When chronic ICI measurement is
activated, the CRT-D records ICI curves over 512 valid heart cycles
(approximately 7 min) every 2 h. The curves are averaged to
minimize the impact of random noise for an enhanced signal-to-
noise ratio. The CRT-D device can be programmed to collect and
transmit one of the twelve constructed mean ICI curves via Home
Monitoring. Fig. 3 shows an exemplary ensemble of those ICI curves
for one patient. From the average curve, the EDZ, ESZ, SZ, and Zmean
values are derived. The 12 sets of these values generated during a
day are averaged per day, stored in the CRT-D memory, and trans-
mitted via Home Monitoring. The stored ICI data can also be
retrieved conventionally from the CRT-D memory during clinical from ClinicalKey.com by Elsevier on July 14, 2021. 
opyright ©2021. Elsevier Inc. All rights reserved.
Fig. 2. Example of an ICI raw data recording during acute clinical settings where the patient was paced at a constant rate of 70 bpm. Markers at the top depict the time points of
paced events in the right atrium, and right and left ventricle, respectively. ICIr depicts the raw ICI signal sampled at 128 Hz as a result of subthreshold current injection (biphasic,
600 mA, 30 msec) and voltage measurement after sampling, demodulation, amplification, low-pass filtering, and offset-correction. ICIb depicts bundled ICI curves from a corre-
sponding 1-min recording aligned by ventricular pace markers where blanked periods were used to cut out pacing artefacts. ICIm depicts the representative ICI (mean curve,
solid ± SD curves, dotted) after bundle-averaging and moving-average-smoothing. SZ is finally calculated as the difference of the maximum and minimum impedance of the mean
curve. ECG, surface electrocardiogram; EDZ: end-diastolic ICI; ESZ: end-systolic ICI; ICI: intracardiac impedance; LVp: left ventricular pace; RAp: right atrial pace; RVp: right
ventricular pace; SZ: stroke impedance.
Fig. 3. Example plot of a patient’s mean ICI curves (chronic measurement). Curves were collected and transmitted daily via Home Monitoring by the CRT-D device over one month
(n ¼ 31). Each of the mean curves ICIm resulted from an averaging of 512 ICI curves taken during a night-time window. Right side depicts a representative (averaged) ICI (mean
curve, solid ± SD curves, dotted) and exemplary calculated ICI parameters. CRT-D, cardiac resynchronization therapy defibrillator; EDZ: end-diastolic ICI; ESZ: end-systolic ICI; ICI:
intracardiac impedance; SZ: stroke impedance; Zmean: mean ICI.
P.-P.H.M. Delnoy, K.-J. Gutleben, N.E. Bruun et al. Indian Pacing and Electrophysiology Journal 21 (2021) 209e218visits and exported to other media for further analysis.
For safety reasons, chronic ICI measurement is temporarily
terminated upon detection of ventricular tachycardia, and no valid
ICI values are generated until the next measurement windowof 512
heart cycles. Detection of ventricular fibrillation results in perma-
nent deactivation of ICI measurement, with the possibility to212
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marily addresses study objectives related to the acute ICI
measurement. from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
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After CRT-D system implantation, 2months were left for lead in-
growth and other processes that may influence lead impedance. At
the 2-month follow-up visit, acute hemodynamic changes were
provoked by overdrive pacing to investigate correlation of echo-
cardiographic parameters and the ICI-based estimate of hemody-
namic changes. ICI was recorded in supine patients at the resting
heart rate and at four overdrive pacing rates ranging from 10 to 40
beats/min above the resting rate (Fig. 4). In parallel, echocardiog-
raphymeasurements were performed (Fig. 5) and later verified by a
designated echo core laboratory blinded to ICI measurements and
clinical data (Appendix).
Patients were excluded from the acute ICI measurement if they
had any contraindication potentially increasing the risk of over-
drive pacing, such as decompensated HF, symptomatic arrhythmia,
unstable angina pectoris, or myocarditis. Patients excluded at 2
months were readmitted to the overdrive pacing protocol at 3
months if contraindications resolved.
For the study objectives related to the chronic ICI measure-
ments, patients were followed for up to 9 months after implanta-
tion. Chronic ICI measurements and Home Monitoring function
were activated to assess the relation of ICI towards clinical events
and the potential utility of ICI for continuous monitoring of slow,
persisting hemodynamic changes.
2.6. Primary hypothesis
We hypothesized that an averaged intra-individual correlation
coefficient r between acutely measured SZ and the aortic velocity
time integral (Ao-VTI, i.e. stroke volume) determined by continuous
wave Doppler would be significantly larger than 0.65.
2.7. Statistical methods
Sample size calculationwas based on experiences from previous
studies, resulting in an estimated correlation coefficient of 0.75
with a variance of 0.25. Assuming a drop-out rate of 25% and a
technical failure rate of 4%, a sample size of 60 enrolled patients was
needed for a required threshold for the primary hypothesis of
r¼ 0.65, a significance level of a¼ 0.05, and a statistical power of 1-
b ¼ 0.8.
The primary hypothesis was evaluated using a one-sided t-test.Fig. 4. Overdrive pacing protocol for acute intracardiac impedance measurements in a contr
always in the same order, resulting in an approximately 45-min long measurement protoc
213
Downloaded for Anonymous User (n/a) at Aalborg Hospital
For personal use only. No other uses without permission. Previously, the patient-individual Pearson correlation coefficients
were transformed by Fisher’s z-transform to approximate a normal
distribution. Normality of the distribution was assessed using
Kolmogorov-Smirnov-Lilliefors and Shapiro-Wilk tests. We calcu-
lated Fisher’s z-transforms by the formula z¼ 0.5∙ln((1þr)/(1-r)) to
account for normalization of data. Retransformation was based on
the formula r¼(exp(2∙z)-1)/(exp(2∙z)þ1)).
According to Figs. 4 and 5, up to 30 value pairs consisting of SZ
and Ao-VTI were determined for each patient (6 samples x 5 heart
rate stages). The statistical analysis plan pre-specified to average
three subsequently measured samples at the same heart rate in
order to reduce measurement noise, which cut the number of value
pairs per patient from 30 to 10. A single correlation coefficient was
calculated in the end from these 10 value pairs.
For descriptive statistics, categorical variables are summarized
by absolute and relative frequencies, and continuous variables are
summarized as mean ± standard deviation (SD). Data analysis and
statistical tests were implemented in Matlab (R2013b, statistics
toolbox V8.3, Math Works Inc., Natick, MA, USA). The test of the
primary hypothesis was verified by means of IBM SPSS Statistics
software, version 23.0 (SPSS Inc., Chicago, IL, USA).2.8. Correction of EDZ calculation principle
Before performing the final statistical test for the primary hy-
pothesis, we reviewed acute ICI data in a subset of patients and
realized that in some patients the minimum ICI value during the
heart cycle in the averaged ICI curve lied outside an expected end-
diastolic timewindow. This implied that the true EDZ value was not
always equal to the minimum of the whole ICI curve. We assume
that the anomalies in the averaged signal were partly due to late
pacing artefacts with too short blanking times or due to impacts of
lead motions or fusion beats, in combination with the rules for
filtering, smoothing, aligning and averaging the raw signals. In
former studies [11e14], predefined end-systolic and end-diastolic
time windows were used within which ESZ and EDZ should be
found as the maximum and the minimum of ICI, respectively.
Therefore, we decided to resume the previous definition of EDZ and
adapt the calculation of EDZ to be determined again as the mini-
mum within a predefined end-diastolic time window. The original
test algorithm was therefore slightly modified in that EDZ was
selected as the minimum impedance during an 80-msec end-
diastolic window prior to biventricular pacing pulse rather thanolled clinical setting. Five stages of heart rates, including intrinsic atrial rate, were used
ol per patient. bpm: beats per minute.
 from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
Fig. 5. The investigational scheme for each stage of heart rate from Fig. 4. After the initial settling phase at a new rate, six samples were taken of both impedance recording (1 min
per sample) and Ao-VTI measurement by CW Doppler (3e4 beat captures recorded for 3 times consecutively in an apical 5-chamber view, with acquisition from the left ventricular
outflow tract). Ao-VTI: Aortic Velocity Time Integral; CW: Continuous Wave.
P.-P.H.M. Delnoy, K.-J. Gutleben, N.E. Bruun et al. Indian Pacing and Electrophysiology Journal 21 (2021) 209e218the minimum impedance during the entire heart cycle.3. Results
3.1. Patients and CRT-D systems
During a period of 23 months, 68 patients were enrolled in the
study, and 63 of them were successfully implanted with a CRT-D
system enabling ICI measurements. The implanted device models
were Lumax 740 HF-T (n ¼ 41), Iforia 7 HF-T (n ¼ 11), Iforia 5 HF-T
(n ¼ 8), Ilesto 7 HF-T (n ¼ 2), and Idova 7 HF-T (n ¼ 1).3.2. Drop-outs before completion of acute ICI measurement
In the period between implantation and the 2-month follow-up,
one patient died and seven patients were excluded based on a pre-
defined drop-out criterion, mainly echocardiographic one, exposed
by data verification at the core laboratory. The rest of patients
(n ¼ 55) attended the 2-month follow-up, and most of them
(n ¼ 49) underwent the overdrive pacing protocol for acute ICI
measurement, either at 2 months (n ¼ 43) or at 3 months (n ¼ 6).
Six patients did not undergo acute ICI measurements, three because
of late discontinuation from the study (informed consent with-
drawal or a drop-out criterion) and three because we already had a
sufficient number of completed acute procedures.
Of a total of 49 acute ICI data sets, 40 qualified for the test of
primary hypothesis. Nine data sets did not qualify due to the
missing reference echocardiographic data (n ¼ 2), a drop-out cri-
terion of post-implant lead revision (n ¼ 2, discovered late), and
violation of pre-defined validity rules for the acute data set (n ¼ 5).
The latter included the failure to achieve at least 4 stages of heart
rate during overdrive pacing protocol (n ¼ 3) and insufficient
strength (<14%) of the heart-rate-dependent Ao-VTI trend (n ¼ 2),
which reflects the efficacy of the overdrive pacing protocol in
provoking a sufficient hemodynamic change with a pre-specified
minimum strength.214
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Table 1 shows baseline characteristics of the 68 enrolled pa-
tients and of 40 patients contributing to the primary hypothesis. All
but one patient in the analysis population were in sinus rhythm,
with a mean resting rate of 69 ± 12 beats/min. Mean QRS duration
was 171 ± 13 msec, and 88% of patients had left bundle branch
block. The LVEF was markedly impaired (29 ± 5%) and LVEDD
increased (65±7 mm). The RV leads in the analysis populationwere
placed in the septal area (48%) or in the apex (45%). The location of
the LV lead tip along the long axis was predominantly medial (78%
[40% posterolateral-medial, 30% lateral-medial]), and in other pa-
tients either basal (15%) or apical (8%).3.4. Results of acute ICI measurements
Acute echo and ICI measurements are illustrated in Fig. 6. With
increasing heart rate, a clear stepwise reduction of both Ao-VTI and
SZ was observed, associated with a slight increase in EDZ and Zmean,
and with no clear ESZ trend. Modification of the test algorithm
generated slightly different EDZ and SZ values in comparison to the
original algorithm, whereas ESZ and Zmean were not affected. With
the modified algorithm, EDZ was commonly estimated somewhat
higher compared to the original algorithm due to the introduced
end-diastolic timewindow before biventricular paces withinwhich
EDZ was now correctly calculated as the minimum. Thus, taking
EDZ as a minimum late after pace was avoided.
All 10 value pairs (SZ þ Ao-VTI) were attained in 26 patients
(65%), nine pairs in seven patients (18%), eight pairs in four patients
(10%), and seven pairs in three patients (8%).
Inter-patient comparison tests were additionally performed for
the ODP subgroups of patients with RV lead implanted in septal
position (n ¼ 19, 47.5%) versus those with RV lead in apex position
(n ¼ 18, 45.0%). Within single heart rate stages, there were no
significant differences of ICI values found for any of the ICI pa-
rameters between the two subgroups. from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
Table 1
Baseline characteristics of the patients.
Enrolled Patients (n ¼ 68) Analysis Population (n ¼ 40)
Demographics
Age [years] 66 ± 9 67 ± 9
Male gender 50 (74%) 29 (73%)
Height [cm] 175 ± 8 176 ± 9
Weight [kg] 85 ± 16 84 ± 17
Blood pressure
Systolic [mmHg] 123 ± 16 125 ± 18
Diastolic [mmHg] 73 ± 10 73 ± 11
Hypertension 45 (66%) 25 (63%)
ECG diagnosis
Sinus rhythm 66 (97%) 39 (98%)
Atrial paced rhythm 3 (4%) 1 (3%)
Heart rate at rest [beats/min] 71 ± 15 69 ± 12
QRS duration [msec] 170 ± 13 171 ± 13
Left-bundle branch block 62 (91%) 35 (88%)
Right-bundle branch block 4 (6%) 3 (8%)
Paroxysmal atrial fibrillation 6 (9%) 2 (5%)
Persistent atrial fibrillation 0 (0%) 0 (0%)
Heart failure related data
NYHA class II 34 (50%) 23 (58%)
NYHA class III 34 (50%) 17 (43%)
LVEF [%] 26 ± 5 29 ± 5
LVEDD [mm] 65 ± 7 65 ± 7
Dilated cardiomyopathy 55 (81%) 33 (83%)
Ischemic etiology 32 (47%) 19 (48%)
Mitral regurgitation 52 (77%) 28 (70%)
Comorbidities
Coronary artery disease 37 (54%) 22 (55%)
Myocardial infarction 28 (41%) 17 (43%)
Stroke 7 (10%) 3 (8%)
COPD 6 (9%) 5 (13%)
Diabetes mellitus 20 (29%) 11 (28%)
Renal insufficiency 12 (18%) 5 (13%)
Major medications
Beta blocker 63 (93%) 38 (95%)
Diuretics 56 (82%) 32 (80%)
ACE inhibitor 49 (72%) 27 (68%)
Spironolactone 42 (62%) 24 (60%)
AT receptor blocker 15 (22%) 10 (25%)
Data are mean ±SD or number (percent).
ACE: Angiotensin Converting Enzyme; AT: Angiotensin; COPD: chronic obstructive pulmonary disease; LVEDD: left ventricular end-diastolic
diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.
P.-P.H.M. Delnoy, K.-J. Gutleben, N.E. Bruun et al. Indian Pacing and Electrophysiology Journal 21 (2021) 209e2183.5. Primary study hypothesis
The mean intra-individual correlation coefficient between SZ
and Ao-VTI was rmean ¼ 0.797, with a lower confidence interval
bound of 0.709. This is significantly larger than the hypothesized
rmean of 0.65 (p ¼ 0.007). The primary hypothesis is therefore met.
As explained above (section 2.8.), this is obtained with a modified
method of EDZ calculation, in which a minimum ICI within an 80-
msec end-diastolic window was taken as EDZ. With the non-
modified method (EDZ equal to the minimum ICI during the
entire heart cycle), a lower rmean (0.688) and a lower confidence
interval bound (0.574) were obtained, not fulfilling the primary
hypothesis (p ¼ 0.272).
Table 2 illustrates the distribution of patient-individual r values
and visualizes the benefit of modified EDZ calculation. The re-
introduction of an end-diastolic time window for EDZ calculation
led to an improvement of the correlations in the big majority of
patients (n¼ 38, 95%). After the modification, 29 patients (73%) had
a relatively strong (r between 0.658 and 0.997) statistically signif-
icant correlation between SZ and Ao-VTI. Additional six patients
(15%) exhibited an acceptable trend with r > 0.400 and p  0.25.
The remaining five patients (13%) showed a weak (n ¼ 2) or
reversed (n ¼ 3) correlation. Reversed correlation was associated
with an atypical LV lead tip position, other than posterolateral-215
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original EDZ method were 22 patients (55%) with a significant
correlation, seven (18%) with good trend, and 11 (28%) with a weak
or reversed correlation.4. Discussion
BIO.Detect HF II is the first non-invasive study of ICI, utilizing the
novel ICI measurement feature integrated in a standard CRT-D
device. After adjusting the calculation principle to ensure that
EDZ lies within an expected end-diastolic window, the correlation
coefficient between SZ (the pre-selected ICI parameter) and Ao-VTI
(determined by echocardiography) was sufficiently strong and
statistically significant, meeting the primary hypothesis.
The ICI measured ‘across the heart’ should not be mixed up with
the intrathoracic impedance measured ‘across the lung’ (between
RV lead and device case) to monitor lung oedema formation in HF
patients, which did not have a significant effect on patient out-
comes [19].4.1. Previous research on ICI
The concept of estimating hemodynamic changes by ICI was first
explored in animal studies (2006e2009) [10e12]. ICI wasmeasured from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
Fig. 6. Results of acute echo and ICI measurements averaged for all patients (mean ± SD). Stages 1e5 are ordered along X-axis according to increasing heart rate. The modified
algorithm affected only SZ and EDZ. Ao-VTI: aortic velocity time integral measured by continuous wave Doppler; bpm: beats per minute; EDZ: end-diastolic ICI; ESZ: end-systolic
ICI; ICI: intracardiac impedance; IR: intrinsic rate; mod.: modified algorithm; SZ: stroke impedance (SZ ¼ ESZ - EDZ); Zmean: mean ICI.
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epicardial leads screwed into the mid-lateral LV wall [10] or along a
basal-apical line [11,12]. Acute hemodynamic changes were
induced by overdrive pacing [10] and/or graded isoprenaline [10] or
dobutamine [12] infusion. In the first study, the correlation be-
tween LV conductance and stroke volume in six healthy mongrel
dogs was robust and significant (rmean ¼ 0.89 [overdrive pacing]
and 0.97 [isoprenaline]) [10].
In the second study, HF was induced in nine mini-pigs by 3
weeks of high-rate pacing. The resulting hemodynamic deteriora-
tion was characterized by reduced mean LVEF (71% / 48%),
increasedmean end-diastolic pressure (12/ 26mmHg), increased
mean end-diastolic volume (by 20%), and a decreased mean EDZ
(by 33%). EDZ correlated with end-diastolic pressure
(rmean ¼ 0.81, p < 0.001) [11].
In the third study, acute hemodynamic changeswere induced by
dobutamine infusion in failing hearts of five mini-pigs after 3
weeks of high-rate pacing. Significant correlation was found be-
tween EDZ and end-diastolic pressure (rmean ¼ 0.82, p < 0.001)
and between SZ and stroke volume (rmean ¼ 0.88, p < 0.001) [12].
After promising animal data, Bocchiardo et al. conducted an
acute proof-of-concept study during CRT(-D) system implantation
or electrophysiology study in 14 patients with dilated cardiomy-
opathy (2010) [13]. In contrast to animal studies, the defibrillation
coil was predominantly used instead of the ring electrode of an RV
lead. Acute hemodynamic changes were induced by overdrive
pacing and measured invasively by a tip manometer catheter as
stroke volume changes derived from the aortic blood pressure. The
strong, stable correlation between SZ and stroke volume
(r ¼ 0.82 ± 0.16) was regarded as a proof that implant-based
continuous monitoring of cardiac function by ICI measurements is
feasible [13]. The respiratory influencewas visible in the impedance
traces, necessitating an averaging of ICI curves over several mi-
nutes, as implemented in the Lumax 740 HF-T and successors de-
vices [13]. In an additional study in the same patient cohort during216
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bility of optimizing LV lead site, atrioventricular delay, and inter-
ventricular delay by ICI (i.e., SZ and ESZ) [14]. Furthermore,
Kühne et al. investigated ICI during CRT implantation in patients
with chronic infarction and documented wall motion abnormal-
ities. Using the arterial pulse contour method to derive hemody-
namics along with ICI, they also suggested the impedance as a valid
parameter to estimate stroke volume or to guide optimization of
CRT timing [15].
4.2. Limitations
There is a variety of impact factors on ICI which may be sug-
gested from the theory behind it, i.e. from the fact that the
measured ICI signal in the described 4-terminal configuration de-
pends 1) on the conductivity of the tissue between the involved
electrodes, 2) on the spacing between the electrodes, and 3) on the
tilt angle between the RV and LV lead. Every factor affecting this
configuration may also “negatively” affect ICI, e.g. inappropriate
lead positions, lead movements, changes in body position, changes
in heart geometry, and changes in the conductivity of blood and
tissue.
The long-lasting process of gathering a single ICI data set
demonstrates the technical challenges that exist to reliably mea-
sure ICI signals at a low milli-ohm level in contrast to the larger
ohm level known for other impedances like thoracic impedance.
This becomes particularly obvious when looking at the elaborate
(time and storage-consuming) averaging of many beat-to-beat ICI
curves to a final ICI mean curve in order to enhance the overall
signal-to-noise ratio.
Our study focused on the short-term correlation between SZ
and echo Ao-VTI in a controlled clinical setting with the patient in
supine position. During ICI data inspection, it turned out that it was
necessary to slightly modify the prescribed algorithm for EDZ
calculation (as the minimum of the whole ICI curve) and adapt it from ClinicalKey.com by Elsevier on July 14, 2021. 
Copyright ©2021. Elsevier Inc. All rights reserved.
Table 2
Correlation Coefficient R between SZ and Ao-VTI (Descending order of R).
Patient Rank Modified Algorithma Original Algorithmb
R P-value R P-value
1 0.997 <0.001 0.984 <0.001
2 0.982 <0.001 0.962 <0.001
3 0.977 <0.001 0.962 0.001
4 0.974 <0.001 0.952 <0.001
5 0.963 <0.001 0.940 <0.001
6 0.934 0.002 0.932 0.001
7 0.928 <0.001 0.896 <0.001
8 0.924 <0.001 0.880 0.001
9 0.909 <0.001 0.877 0.001
10 0.895 <0.001 0.867 0.001
11 0.880 0.001 0.859 0.006
12 0.876 0.004 0.857 0.002
13 0.873 0.005 0.854 0.002
14 0.853 0.002 0.851 0.004
15 0.850 0.004 0.815 0.004
16 0.849 0.002 0.803 0.009
17 0.847 0.002 0.774 0.009
18 0.841 0.002 0.706 0.023
19 0.828 0.003 0.700 0.024
20 0.825 0.022 0.688 0.028
21 0.817 0.013 0.681 0.030
22 0.808 0.015 0.679 0.031
23 0.789 0.007 0.635 0.126
24 0.789 0.011 0.631 0.050
25 0.718 0.019 0.628 0.052
26 0.707 0.022 0.627 0.052
27 0.706 0.034 0.544 0.130
28 0.700 0.024 0.506 0.135
29 0.658 0.039 0.491 0.179
30 0.572 0.108 0.339 0.338
31 0.556 0.095 0.277 0.439
32 0.543 0.105 0.223 0.564
33 0.515 0.156 0.054 0.898
34 0.462 0.178 0.034 0.937
35 0.401 0.250 0.024 0.951
36 0.231 0.520 0.044 0.904
37 0.145 0.756 0.092 0.800
38 0.088 0.822 0.258 0.471
39 0.401 0.250 0.342 0.334
40 0.768 0.009 0.681 0.092
Mean 0.797 0.688
SD 0.645 0.615
CI lowc 0.709 0.574
P-valued 0.007 0.272
Ao-VTI: aortic velocity time integral measured by continuous wave Doppler; EDZ:
end-diastolic ICI; ESZ: end-systolic ICI; ICI: intracardiac impedance; SD: standard
deviation; SZ: stroke impedance (SZ ¼ ESZ - EDZ).
a EDZ ¼ minimum ICI within 80-msec end-diastolic window.
b EDZ ¼ minimum ICI during the entire heart cycle.
c The lower 95% confidence interval (CI) boundary.
d Significance of the mean value compared with the hypothesized mean value of
0.65.
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was restricted to a predefined end-diastolic time window.
In the uncontrolled chronic setting, ICI sets will be measured for
safety reasons by use of a lower current amplitude. Consequently,
measurement times for averaging ICI must be prolonged to keep a
similar signal-to-noise ratio. This might conversely lead to non-
stationary measurement conditions. However, our first results
showed satisfactory mean ICI curves as well for the chronic setting.
This suggests that ICI-based applications may also be worth
considering for a long-term monitoring of HF progression by the
Home Monitoring functionality of the CRT-D device.4.3. Device therapy and remote monitoring in heart failure
The prevalence of HF in the adult population in developed217
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[2]. Although an increasing number of HF patients is treated by
implantable-cardioverter defibrillator (ICD) and CRT(-D) devices
capable of reducingmortality andmorbidity, it remains challenging
to prevent symptom worsening, decompensation, and hospital
admissions in ambulatory patients [2]. Implant-based remote
monitoring failed to improve hard clinical outcomes in randomized
controlled trials, except for daily multi-parameter Home Moni-
toring (without a hemodynamic sensor) that reduced all-cause
mortality but not HF hospitalization in a single trial (IN-TIME)
[17,20]. The 2016 ESC Guidelines for the Diagnosis and Treatment of
Acute and Chronic Heart Failure [2] recommend only the IN-TIME
approach and a stand-alone monitor of pulmonary artery pres-
sure (CardioMEMS, reduced HF hospitalization but not mortality)
[7,9] as the remote monitoring strategies capable of improving
clinical outcomes in symptomatic HF patients, with the class of
recommendation IIb (may be used) and the level of evidence B
(single trial evidence). Further tools are needed in the future to
improve early recognition of HF progression or, even better, to shift
from crisis detection to health maintenance [8]. Having this in
mind, it might be of major benefit to add hemodynamic parameters
to the current remote HF diagnostics.
The ICI measurement bears some potential and is readily
available technically, not requiring implantation of additional ma-
terial beyond that of a standard CRT(-D) system. It remains to
evaluate the utility of ICI coupled with remote monitoring in
guiding medical therapy and optimizing CRT. Another
hemodynamic-based concept has been tested recently, the peak
endocardial acceleration (PEA) sensor integrated in an RV or right
atrial lead to assess cardiac contractility [21]. PEA-based algorithms
can be utilized to optimize CRT automatically on a weekly basis, by
adapting atrioventricular and inter-ventricular delays. However, no
remote monitoring of this hemodynamic sensor is currently avail-
able [21]. Other hemodynamic sensors, such as RV pressure or left
atrial pressure, are also under development [4,7].5. Conclusions
Intracardiac impedance measured by implanted CRT-Ds corre-
lated well with the aortic velocity time integral (stroke volume)
determined by echocardiography in a controlled clinical setting. As
an integral part of a standard CRT-D system capable of remote
monitoring, the novel sensor has potential to continuously track
changes of cardiac hemodynamics.Funding
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